Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04494503 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Dec 2024 to Oct 20, 2024v7
  2. Secondary endpoints revised (5) Site contacts updated at 1 of 18 sitesv6 Show 1 more changeShow less
    • Site contacts updated at 1 of 18 sites

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Aug 2023 to Dec 2024 Completion date: Aug 2024 to Dec 2025v5 Show 1 more changeShow less
    • Completion date: Aug 2024 to Dec 2025
  4. Primary completion date: Aug 2022 to Aug 2023 Completion date: Aug 2023 to Aug 2024v4 Show 1 more changeShow less
    • Completion date: Aug 2023 to Aug 2024
  5. Study sites: 1 to 18 Eligibility criteria expanded, about 7 words · Secondary endpoints: 3 to 5v3 Show 2 more changesShow less
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: 3 to 5

    See this version in full on ClinicalTrials.gov ↗

  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Aug 2020 to Aug 31, 2020 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Aug 2020 to Aug 31, 2020
    • Site details revised
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.
Trial Details
NCT Number NCT04494503
Lead Sponsor Ascentage Pharma Group Inc.
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 123 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov